# Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia

> **NCT06869265** · PHASE2 · RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 56 (estimated)

## Conditions studied

- Acute Myeloid Leukemia (AML)
- High Risk Acute Myeloid Leukemia(AML)
- Relapsed/Refractory Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** Thiotepa ;busulfan;fludarabine

## Key facts

- **NCT ID:** NCT06869265
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2028-04-01
- **Final completion:** 2029-04-01
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2025-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06869265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06869265, "Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06869265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*